NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its…
FAST NEWS: JW Therapeutics’ loss narrows on lower selling expenses
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) reported on Tuesday its net loss for the first half of 2023 narrowed 11.4% year-on-year to 380 million yuan ($52.1 million). Looking…
Gracell Bio Shares Tumble as Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Receipt of ‘orphan drug’ designation for company’s CAR-T cancer drug in the U.S. will bring financial incentives, but also underscores drug’s limited market potential Key takeaways Gracell Bio stands to…
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
-
Yalla revenue growth returns to double-digits ahead of new gaming push
YALA.US
